Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Summary

• I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption.
• The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams.
• International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence.
• Technical analysis indicates bullish momentum with no signs of reversal, supported by positive financials and key growth drivers, making ESPR a buy.